Dominant Dystrophic Epidermolysis Bullosa (EB)

Welcome to the EB Road Map

Looking for the Dominant Dystrophic Epidermolysis Bullosa My Med Team Social Network?

Click on the graphic below.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

FDA Approves Radicava (edaravone) to Treat ALS

Regenerative Neurobiology

ALS Treatment Updates

  • ALS walk to be held next weekend at Cosmo-Bethel Park 17 Aug 2017 23:39 Columbia Missourian COLUMBIA — The annual Columbia ALS walk is something "you can wrap your heart around," Bill Byington said. In 2014, after what Byington described as "a very private, hard battle," his father died of ALS, also known as Lou Gehrig's …
  • Quad Cities Walk to Defeat ALS Brings Hope to Iowans with ALS 17 Aug 2017 19:58 River Cities Reader The ALS Association Celebrates Supporters in the Quad Cities Thanks to generous support for the ALS Association, the first ALS treatment drug in 22 years was approved this past May. While the search continues for more treatments and cure, community …
  • GHS Neurological Institute recognized by ALS Association 12 Aug 2017 01:13 WYFF GHS Neurological Institute recognized by ALS Association Copy Link Copy {copyShortcut} to copy Link copied! Updated: 8:30 PM EDT Aug 11, 2017 Hide Transcript Show Transcript WEBVTT BRENNAN: GHS IS NOW THE ONLYHOSPITAL IN SOUTH CAROLINARECOGNIZED BY THE …
  • Two ALS patients in Buffalo first in U.S. to receive new drug 11 Aug 2017 19:24 United Press International (UPI) Aug. 11 (UPI) -- Two patients at the DENT Neurologic Institute near Buffalo, N.Y., will be the first in the nation to receive the newest drug to treat ALS in more than 20 years. Amyotrophic lateral sclerosis, or ALS, is a progressive degenerative disease …
  • Amyotrophic Lateral Sclerosis (ALS) Treatment Market Is Expected To Reach US$ 306.6 Mn By 2025 10 Aug 2017 14:57 PR Log New Market Research Reports Title "Amyotrophic Lateral Sclerosis (ALS) Treatment Market Is Expected To Reach US$ 306.6 Mn By 2025 – Credence Research" Has Been Added to Credenceresearch.com Report Database.     SAN JOSE, Calif. - Aug. 10, 2017 - …
  • Nancy Frates Says New ALS Treatment Offers Hope 09 Aug 2017 03:29 CBS Boston BOSTON (CBS) – A powerful wave of hope moving through the ALS community – the FDA has approved a drug for the first time in more than two decades that slows the symptoms of the devastating disease. Radicava has shown promising signs in Japan – slowing the …
  • First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S. 08 Aug 2017 15:07 salesandmarketingnetwork.com JERSEY CITY, N.J., Aug. 8, 2017 -- (Healthcare Sales & Marketing Network) -- Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral …
  • U.S. STOCKS ON THE MOVE- Barnes & Noble, Freeport-McMoRan, Interpublic 25 Jul 2017 19:04 The Times of India * Eikon search string for individual stock moves: STXBZ * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P hit a record and the Dow was higher on Tuesday, …
  • Wins $15.9M CIRM Grant for Phase III Trial of ALS Cell Therapy 22 Jul 2017 10:40 4-traders BrainStorm Cell Therapeutics has won a $15.9 million grant from Californias regenerative medicine agency toward a Phase III trial of its amyotrophic lateral sclerosis (ALS) cell therapy candidate NurOwn. The governing board of the California Institute for …
  • BrainStorm Wins $15.9M CIRM Grant for Phase III Trial of ALS Cell Therapy 21 Jul 2017 15:22 Genetic Engineering News BrainStorm said the patient population will be optimized to include faster-progressing patients who showed superior outcomes in NurOwn’s Phase II ALS trial (NCT02017912).  The company reported positive topline results from that 48-patient trial in July …

 

Showing listings 1-9 of 4323

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

PKAN Groups

 

http://mycitymed.com/groups/pkan/

Featured

View all

PKAN Updates

  • Retrophin Inc Has Returned 28.1% Since SmarTrend Recommendation (RTRX) 22 Aug 2017 05:38 Tradingcharts.com Aug 21, 2017 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Retrophin Inc (NASDAQ:RTRX) on June 19th, 2017 at $18.41. In approximately 2 months, Retrophin Inc has returned 28.14% as of today's recent price of $23.59. In the …
  • Retrophin: Updates To Thesis 21 Aug 2017 18:42 Seeking Alpha Shares of Retrophin (NASDAQ:RTRX) have climbed by around 50% since I first started covering the company. Year to date, the share price has risen by nearly 25%. Key elements of the bull thesis in my most recent entry included the following: An $800 million …
  • Grandmother opens up about grandson's terminal illness 14 Aug 2017 22:54 Charleston Daily Mail Erin Heasley started noticing something was wrong with her son, Riley, when he was only nine months old in 2009. He was not developing at the same rate as other babies his age in Longmont, Colorado. He started sitting up far later than he should have done …
  • Ride for Riley to benefit research into Longmont boy's rare disease 13 Aug 2017 16:59 The Daily Camera If you go What: Ride for Riley When: 10 a.m. Saturday Where: Starts at Garden Gate Cafe, 7960 Niwot Road Cost: $25 per vehicle and $10 per additional poker tally card More info: bit.ly/2uwzbLU A Longmont family is hoping to put a dent in a $2 million …
  • Retrophin's (RTRX) CEO Steve Aselage on Q2 2017 Results - Earnings Call Transcript 11 Aug 2017 20:25 Seeking Alpha Retrophin, Inc. (NASDAQ:RTRX) Q2 2017 Earnings Conference Call August 9, 2017 4:30 PM ET Executives Chris Cline – Vice President-Investor Relations Steve Aselage – Chief Executive Officer Bill Rote – Senior Vice President and Head-Research and Development …
  • Buy vet and pet crematoria firm CVS 25 Jun 2017 16:17 Daily Mail We round up the Sunday newspaper share tips. This week, Midas looks at vet chain CVS Group and middle class clothing brand Joules, while the Sunday Telegraph analyses Royal Mail.  The Sunday Times meanwhile delves into why The Lady from the Provvy has …
  • Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued Patents in the United States and Europe 01 Jun 2017 12:23 GlobeNewswire SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have each issued a patent covering the Company’s product candidate …
  • The Investment Case For Retrophin 05 May 2017 16:57 Seeking Alpha Retrophin (NASDAQ:RTRX) is trading at an enterprise value of around $450 million while having three marketed products and what looks like a solid pipeline and a robust balance sheet that allows the company to pursue additional deals. I avoided Retrophin …
  • Retrophin's (RTRX) CEO Steve Aselage on Q1 2017 Results - Earnings Call Transcript 05 May 2017 00:32 Seeking Alpha Retrophin, Inc. (NASDAQ:RTRX) Q1 2017 Earnings Conference Call May 4, 2017 4:30 p.m. ET Executives Chris Cline - VP, IR Steve Aselage - CEO Neil McFarlane - COO Laura Clague - CFO Bill Rote - SVP, and Head of R&D Analysts Tim Lugo - William Blair Do …
  • Retrophin Reports First Quarter 2017 Financial Results 04 May 2017 20:09 GlobeNewswire Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017 Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGS First quarter revenues rose 16 percent to $34 million SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. ( …
  • Retrophin to Report First Quarter 2017 Financial Results 20 Apr 2017 20:38 GlobeNewswire April 20, 2017 16:30 ET | Source: Retrophin, Inc. SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. …
  • Retrophin Appoints Ron Squarer to Board of Directors 12 Apr 2017 20:35 GlobeNewswire SAN DIEGO, April 12, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Ron Squarer to the Company’s Board of Directors, effective immediately. Mr. Squarer is chief executive officer and a director of Array BioPharma …
  • John A. Orwin Joins Retrophin Board of Directors 23 Mar 2017 21:32 GlobeNewswire SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company’s Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc …
  • NephCure Kidney International® Launches the NephCure Accelerating Cures Institute® 21 Mar 2017 12:11 Kait Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please …
  • Small Cap Retrophin Has Room to Recover 03 Mar 2017 14:37 SmallCap Network On Thursday, our Under the Radar Movers newsletter suggested going long on small cap biopharmaceutical stock Retrophin Inc (NASDAQ: RTRX): “Two views of RTRX today. The short-term one shows how there's been a high-volume buy-in this week, and that …
  • Retrophin's (RTRX) CEO Steve Aselage on Q4 2016 Results - Earnings Call Transcript 02 Mar 2017 03:15 Seeking Alpha Retrophin, Inc. (NASDAQ:RTRX) Q4 2016 Results Conference Call March 01, 2017 05:00 PM ET Executives Chris Cline - Senior Director, IR Steve Aselage - CEO Neil McFarlane - COO Laura Clague - CFO Analysts Joseph Schwartz - Leerink Partners Liisa Bayko - JMP …
  • Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results 01 Mar 2017 21:10 GlobeNewswire Phase 3 trial of sparsentan in FSGS to initiate in second half of 2017; Interim analysis of proteinuria to serve as basis for NDA filing for accelerated approval Full year 2016 revenue grew 34% over 2015 to $134 million Conference call today at 5:00 p.m. …
  • Retrophin to Report Fourth Quarter and Full Year 2016 Financial Results 15 Feb 2017 21:47 GlobeNewswire February 15, 2017 16:30 ET | Source: Retrophin, Inc. SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report fourth quarter and full year 2016 financial results on Wednesday, March 1, 2017 after the close …
  • Retrophin Appoints William Rote Senior Vice President, Research and Development 13 Feb 2017 22:47 PharmiWeb.com Posted on: 13 Feb 17 SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced William “Bill” Rote, Ph.D. has been appointed senior vice president, research and development, effective immediately. Dr. Rote will oversee all …
  • Appoints Elizabeth Reed General Counsel 05 Jan 2017 08:57 4-traders (GlobeNewswire) - Retrophin, Inc.(NASDAQ:RTRX) today announced Elizabeth Reed has been appointed general counsel and corporate secretary, effective immediately. Ms. Reed will be responsible for overseeing the Companys general legal, intellectual property, …

This page does not yet have a sponsor.

Interested in becoming one?  Email us at sponsor@mycitymed.com to learn more.

[google_news query=’als’ topic=snc topic=t topic=b topic=s topic=m]

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2017 My City Med. All Rights Reserved.

or

Log in with your credentials

or    

Forgot your details?

or

Create Account

Skip to toolbar